Is evantuzumab available in the country? How can patients purchase this drug in the country?

Amivantamab is a new type of antibody drug, a bispecific antibody, mainly used to treat EGFR mutation-positive non-small cell lung cancer (NSCLC). The drug can effectively inhibit the growth of cancer cells through targeted therapy and works by blocking the EGFR and MET signaling pathways. Evantumumab has been gradually approved globally and has received marketing authorization in multiple countries and regions. According to the latest news, evantumumab has been launched in China, but due to the short launch time of the drug, the supply situation in the domestic market may not be completely stable.

Although evantumumab is already on the market in China, due to its short time on the market, the supply and purchase channels for the drug may not be fully open. Therefore, domestic patients may face difficulty in purchasing the drug directly. Currently, the official launch of evantumumab in China is still in the promotion stage, so it may take some time for patients to obtain the drug at local pharmacies or hospitals. During this period, patients can consult hospitals or related medical institutions to learn about the latest supply of drugs and obtain accurate purchasing channel information.

For patients in urgent need of treatment, if evantumumab is temporarily unavailable in China, patients may consider purchasing the drug through overseas markets. It is understood that evantumumab has been launched in Hong Kong, China, and there is an original version on the Hong Kong market for patients to choose from. The price of evantumumab in Hong Kong is about RMB 10,000 per tube, which may be slightly higher than the price in the domestic market. However, the Hong Kong market is still a viable option for patients who cannot purchase it domestically. When patients purchase drugs in Hong Kong, they need to ensure that they purchase them through formal channels to ensure the quality and safety of the drugs.

With the further promotion of evantumumab in the domestic market and the improvement of the supply chain, domestic patients will be able to purchase the drug more conveniently in the future. When purchasing drugs, patients should pay special attention to the approval number and formal channels of the drug to avoid purchasing fake and shoddy drugs. In addition, before using evantumumab, patients are advised to fully communicate with their doctors to understand the drug's indications, dosage, possible side effects and related treatment options to ensure the safety and effectiveness of the treatment.

Reference materials:https://www.rybrevant.com/